[go: up one dir, main page]

CY1106113T1 - Παραγωγα 4-φαινυλ-πυριδινης ως ανταγωνιστες του υποδοχεα νευροκινινης-1 - Google Patents

Παραγωγα 4-φαινυλ-πυριδινης ως ανταγωνιστες του υποδοχεα νευροκινινης-1

Info

Publication number
CY1106113T1
CY1106113T1 CY20061100918T CY061100918T CY1106113T1 CY 1106113 T1 CY1106113 T1 CY 1106113T1 CY 20061100918 T CY20061100918 T CY 20061100918T CY 061100918 T CY061100918 T CY 061100918T CY 1106113 T1 CY1106113 T1 CY 1106113T1
Authority
CY
Cyprus
Prior art keywords
neurokinin
phenyl
receptor antagonists
pyridine derivatives
receptor
Prior art date
Application number
CY20061100918T
Other languages
English (en)
Inventor
Torsten Hoffmann
Patríck SCHNIDER
Heinz Stadler
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1106113T1 publication Critical patent/CY1106113T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε ενώσεις των γενικών τύπων (ΙΑ) και (IB) στους οποίους R1 είναι (a), (b), (c), (d) ή είναι -NH(CH2)2OH, -NR3C(Ο)CH3 ή -NR3C(O)-κυκλοπροπύλιο, R2 είναι μεθύλιο ή χλώριο, R3 είναι υδρογόνο ή μεθύλιο, R είναι υδρογόνο ή -(CH2)2OH και n είναι 1 ή 2 και φαρμακευτικώς παραδεκτά άλατα δια προσθήκης οξέος αυτών. Αυτές οι ενώσεις έχουν μία καλή συγγένεια προς τον NK-1-υποδοχέα και ως εκ τούτου μπορούν να χρησιμοποιηθούν στην θεραπευτική αγωγή ή πρόληψη ασθενειών που σχετίζονται με αυτόν τον υποδοχέα.
CY20061100918T 2000-07-24 2006-07-04 Παραγωγα 4-φαινυλ-πυριδινης ως ανταγωνιστες του υποδοχεα νευροκινινης-1 CY1106113T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24
EP01960529A EP1305319B1 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PCT/EP2001/008432 WO2002008232A1 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Publications (1)

Publication Number Publication Date
CY1106113T1 true CY1106113T1 (el) 2011-06-08

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100918T CY1106113T1 (el) 2000-07-24 2006-07-04 Παραγωγα 4-φαινυλ-πυριδινης ως ανταγωνιστες του υποδοχεα νευροκινινης-1

Country Status (37)

Country Link
US (2) US6576762B2 (el)
EP (1) EP1305319B1 (el)
JP (1) JP4118673B2 (el)
KR (1) KR100527214B1 (el)
CN (1) CN1192032C (el)
AR (1) AR029875A1 (el)
AT (1) ATE322496T1 (el)
AU (2) AU8200501A (el)
BR (1) BR0112695A (el)
CA (1) CA2416874C (el)
CY (1) CY1106113T1 (el)
CZ (1) CZ2003528A3 (el)
DE (1) DE60118569T2 (el)
DK (1) DK1305319T3 (el)
EC (1) ECSP034446A (el)
ES (1) ES2260265T3 (el)
GT (1) GT200100148A (el)
HR (1) HRP20030031A2 (el)
HU (1) HU229231B1 (el)
IL (2) IL153837A0 (el)
JO (1) JO2321B1 (el)
MA (1) MA26933A1 (el)
MX (1) MXPA03000367A (el)
MY (1) MY129224A (el)
NO (1) NO20030353L (el)
NZ (1) NZ523452A (el)
PA (1) PA8522801A1 (el)
PE (1) PE20020258A1 (el)
PL (1) PL366173A1 (el)
PT (1) PT1305319E (el)
RU (1) RU2276139C2 (el)
SI (1) SI1305319T1 (el)
TW (1) TWI287003B (el)
UY (1) UY26851A1 (el)
WO (1) WO2002008232A1 (el)
YU (1) YU2803A (el)
ZA (1) ZA200300219B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
ATE384053T1 (de) 2002-04-26 2008-02-15 Lilly Co Eli Triazolderivate als tachykininrezeptor- antagonisten
CN1313450C (zh) 2002-04-26 2007-05-02 伊莱利利公司 速激肽受体拮抗剂
EP1556039A2 (en) * 2002-10-11 2005-07-27 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
CN1852712B (zh) 2003-07-03 2010-06-09 弗·哈夫曼-拉罗切有限公司 用于治疗精神分裂症的双重nk1/nk3拮抗剂
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
WO2006002860A1 (en) 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
AU2007267183B2 (en) 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
PL3067349T3 (pl) 2013-11-08 2018-06-29 Kissei Pharmaceutical Co., Ltd. Pochodna karboksymetylopiperydyny
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016149324A1 (en) 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AU751114B2 (en) 1998-03-19 2002-08-08 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use as tachykinin receptor antagonists
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
BR0008489A (pt) * 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
RU2236402C2 (ru) * 1999-02-24 2004-09-20 Ф.Хоффманн-Ля Рош Аг Производные 3-фенилпиридина и фармацевтическая композиция на их основе
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
IL153834A0 (en) * 2000-07-14 2003-07-31 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Also Published As

Publication number Publication date
BR0112695A (pt) 2003-04-22
CA2416874A1 (en) 2002-01-31
AU2001282005B2 (en) 2006-10-19
MY129224A (en) 2007-03-30
RU2276139C2 (ru) 2006-05-10
US20030130508A1 (en) 2003-07-10
UY26851A1 (es) 2002-01-31
AR029875A1 (es) 2003-07-16
CN1192032C (zh) 2005-03-09
EP1305319A1 (en) 2003-05-02
JP2004504400A (ja) 2004-02-12
KR20030015898A (ko) 2003-02-25
PE20020258A1 (es) 2002-04-02
KR100527214B1 (ko) 2005-11-08
HK1058360A1 (en) 2004-05-14
CZ2003528A3 (cs) 2003-09-17
HUP0301272A2 (hu) 2003-08-28
YU2803A (sh) 2006-01-16
CA2416874C (en) 2011-01-18
HRP20030031A2 (en) 2004-02-29
GT200100148A (es) 2002-05-16
EP1305319B1 (en) 2006-04-05
AU8200501A (en) 2002-02-05
PA8522801A1 (es) 2002-09-30
CN1444589A (zh) 2003-09-24
SI1305319T1 (sl) 2006-08-31
ATE322496T1 (de) 2006-04-15
WO2002008232A1 (en) 2002-01-31
NO20030353D0 (no) 2003-01-23
JO2321B1 (en) 2005-09-12
IL153837A (en) 2008-06-05
DK1305319T3 (da) 2006-08-14
ECSP034446A (es) 2003-03-10
HU229231B1 (en) 2013-09-30
ES2260265T3 (es) 2006-11-01
US6624176B2 (en) 2003-09-23
IL153837A0 (en) 2003-07-31
US20020038030A1 (en) 2002-03-28
TWI287003B (en) 2007-09-21
DE60118569D1 (de) 2006-05-18
NZ523452A (en) 2004-07-30
MA26933A1 (fr) 2004-12-20
ZA200300219B (en) 2004-04-08
DE60118569T2 (de) 2007-02-15
US6576762B2 (en) 2003-06-10
MXPA03000367A (es) 2003-05-27
JP4118673B2 (ja) 2008-07-16
PT1305319E (pt) 2006-08-31
PL366173A1 (en) 2005-01-24
NO20030353L (no) 2003-01-23

Similar Documents

Publication Publication Date Title
CY1106113T1 (el) Παραγωγα 4-φαινυλ-πυριδινης ως ανταγωνιστες του υποδοχεα νευροκινινης-1
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
CY1108451T1 (el) Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1105986T1 (el) Παραγωγα ινδολιου χρησιμα ως ανταγωνιστες η3 ισταμινης
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
CY1112286T1 (el) Παραγωγα πυραζολιου χρησιμα για τη θεραπεια γυναικολογικων ασθενειων
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
CY1105907T1 (el) Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης
CY1105688T1 (el) Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
MY138352A (en) Benzothiazole derivatives
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
CY1109498T1 (el) 18-μεθυλο-19-νορ-17-πρεγν-4-ενο-21,17-καρβολακτονες καθως και φαρμακευτικα σκευασματα που τις περιεχουν
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
CY1106924T1 (el) Ενωσεις καρβαμικου για χρηση οσον αφορα την προληψη ή την αγωγη των διαταραχων κινησης
PE20030541A1 (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten